• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Imunon Inc.

    5/28/25 4:15:35 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMNN alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0000749647
    Celsion CORP
    CELSION CORP
    CHEUNG LABORATORIES INC
    Celsion Corporation
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Imunon, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Imunon, Inc.
    Street Address 1 Street Address 2
    997 LENOX DRIVE SUITE 100
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    LAWRENCEVILLE NEW JERSEY 08648-2311 (609) 896-9100

    3. Related Persons

    Last Name First Name Middle Name
    Lindborg Stacy R.
    Street Address 1 Street Address 2
    997 Lenox Drive Suite 100
    City State/Province/Country ZIP/PostalCode
    Lawrenceville NEW JERSEY 08648-2311
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    President and Chief Executive Officer
    Last Name First Name Middle Name
    Tardugno Michael H.
    Street Address 1 Street Address 2
    997 Lenox Drive Suite 100
    City State/Province/Country ZIP/PostalCode
    Lawrenceville NEW JERSEY 08648-2311
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):

    Executive Chairman
    Last Name First Name Middle Name
    Gaiero David
    Street Address 1 Street Address 2
    997 Lenox Drive Suite 100
    City State/Province/Country ZIP/PostalCode
    Lawrenceville NEW JERSEY 08648-2311
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Financial Officer
    Last Name First Name Middle Name
    Eylward Susan
    Street Address 1 Street Address 2
    997 Lenox Drive Suite 100
    City State/Province/Country ZIP/PostalCode
    Lawrenceville NEW JERSEY 08648-2311
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    General Counsel and Corporate Secretary
    Last Name First Name Middle Name
    Faller Douglas
    Street Address 1 Street Address 2
    997 Lenox Drive Suite 100
    City State/Province/Country ZIP/PostalCode
    Lawrenceville NEW JERSEY 08648-2311
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Medical Officer
    Last Name First Name Middle Name
    Anwer Khursheed
    Street Address 1 Street Address 2
    997 Lenox Drive Suite 100
    City State/Province/Country ZIP/PostalCode
    Lawrenceville NEW JERSEY 08648-2311
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Executive Vice President and Chief Scientific Officer
    Last Name First Name Middle Name
    Braun Donald P.
    Street Address 1 Street Address 2
    997 Lenox Drive Suite 100
    City State/Province/Country ZIP/PostalCode
    Lawrenceville NEW JERSEY 08648-2311
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Dentzer James E.
    Street Address 1 Street Address 2
    997 Lenox Drive Suite 100
    City State/Province/Country ZIP/PostalCode
    Lawrenceville NEW JERSEY 08648-2311
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Fritz Frederick J.
    Street Address 1 Street Address 2
    997 Lenox Drive Suite 100
    City State/Province/Country ZIP/PostalCode
    Lawrenceville NEW JERSEY 08648-2311
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Pellizzari Christine
    Street Address 1 Street Address 2
    997 Lenox Drive Suite 100
    City State/Province/Country ZIP/PostalCode
    Lawrenceville NEW JERSEY 08648-2311
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-05-27    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security X Other (describe)
    Warrants and pre-funded warrants to purchase common stock and shares of common stock underlying such warrants

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    H.C. Wainwright & Co., LLC 000000375
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    430 Park Avenue
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10022
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
    X Foreign/non-US
    CALIFORNIA
    FLORIDA
    ILLINOIS
    NEW JERSEY
    NEW YORK

    Recipient
    Recipient CRD Number    None
    Brookline Capital Markets, a division of Arcadia Securities, LLC 000044656
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    600 Lexington Avenue 30th Floor
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10022
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
    X Foreign/non-US
    CALIFORNIA
    FLORIDA
    ILLINOIS
    NEW JERSEY
    NEW YORK

    13. Offering and Sales Amounts

    Total Offering Amount $3,250,001 USD
    or    Indefinite
    Total Amount Sold $3,250,001 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    3

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $227,500 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    In addition to the cash fee above, the Company paid certain expenses and issued a warrant to purchase up to 361,111 shares of the Company's common stock at an exercise price of $0.5625 per share to H.C. Wainwright, LLC.

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Imunon, Inc. /s/ Susan Eylward Susan Eylward General Counsel and Corporate Secretary 2025-05-28

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $IMNN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMNN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY

    Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the company Phase 3 Study enrollment remains ahead of schedule and advances the company toward future BLA filing LAWRENCEVILLE, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced a strategic reorganization that will eliminate headcount not essential to the Phase 3 trial and redefine the job descriptions for additional employees to reduce operating expenses while supporting the co

    2/5/26 8:05:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules

    LAWRENCEVILLE, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 1,939,114 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate of 1,939,114 shares of common stock, in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in-lieu thereof) is being sold together with one warrant to purchase one share of c

    12/30/25 8:30:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026

    Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001's Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILLE, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN) Dear Valued Shareholders, 2025, A Year of Momentum: Advancing Toward a Potential Breakthrough in Ovarian Cancer Treatment As we close out 2025, I am excited to reflect on a year marked by significant clinical progress, robust data validation, and strategic execution that has significantly strengthened IMUNON's position. Our focus on harnessing the power to activate the body's immune system against cancer has yielded com

    12/29/25 11:10:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Braun Donald P bought $29,480 worth of shares (25,000 units at $1.18), increasing direct ownership by 4,188% to 25,597 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    1/28/25 4:18:24 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Lindborg Stacy bought $24,500 worth of Imunon Common Stock (25,000 units at $0.98), increasing direct ownership by 10% to 264,166 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    8/16/24 8:03:50 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman of Board Tardugno Michael H bought $25,750 worth of Imunon Common Stock (25,000 units at $1.03), increasing direct ownership by 8% to 353,346 units (SEC Form 4)

    4 - Imunon, Inc. (0000749647) (Issuer)

    8/16/24 8:01:30 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    SEC Filings

    View All

    Imunon Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Imunon, Inc. (0000749647) (Filer)

    2/5/26 8:05:45 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Imunon Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Imunon, Inc. (0000749647) (Filer)

    1/7/26 5:15:50 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Imunon Inc.

    424B5 - Imunon, Inc. (0000749647) (Filer)

    12/31/25 8:15:19 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Church Jeffrey Wayne claimed ownership of 26 shares (SEC Form 3)

    3 - Imunon, Inc. (0000749647) (Issuer)

    1/20/26 4:07:36 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CFO Bragg Kimberly

    4 - Imunon, Inc. (0000749647) (Issuer)

    1/6/26 4:11:31 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Anwer Khursheed

    4 - Imunon, Inc. (0000749647) (Issuer)

    1/6/26 4:09:31 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Leadership Updates

    Live Leadership Updates

    View All

    IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer

    Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the appointment of Douglas V. Faller, M.D., Ph.D., as chief medical officer, effective February 18, 2025. In this role, Dr. Faller will lead the company's clinical strategy including advancing its lead program IMNN-001 for the treatment of newly diagnosed advanced ovarian cancer, which is on track to enter a Phase 3 pivotal trial in the first quarter of 202

    2/10/25 8:05:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

    Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr. Lindborg has served on IMUNON's board of directors since 2021. Dr. Lindborg assumes the leadership of IMUNON at a pivotal time. Topline results from the Phase 2 OVATION 2 Stud

    5/8/24 8:00:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer, effective December 11, 2023. Dr. Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics. He will report to IMUNON's President and Chief Executive Officer, Dr. Corinne Le

    12/11/23 8:30:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Financials

    Live finance-specific insights

    View All

    IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

    R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced ovarian cancer Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three-month and nine-month periods ended September 30, 2025, and highlighted recent business updates, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed

    11/13/25 7:45:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

    LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. ET on Thursday, November 13, 2025 to discuss financial results for the third quarter ended September 30, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. To participate in the call, interested parties may dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) and ask for the IMUNON Third Quarter 2025 Financial Results Call. A live webcast of the

    11/6/25 8:05:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

    LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market following confirmation from the Nasdaq Hearings Panel. As a result, IMUNON common stock will continue uninterrupted trading on The Nasdaq Capital Market. "Having regained compliance with Nasdaq's minimum bid price listing requirement, investors in IMUNON's stock are assured of efficient liquidity as provided by the exchange. Our ongoing confidence in our listing with the Nasdaq coi

    8/28/25 8:05:00 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Imunon Inc.

    SC 13G - Imunon, Inc. (0000749647) (Subject)

    11/14/24 5:37:34 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Imunon Inc.

    SC 13G/A - Imunon, Inc. (0000749647) (Subject)

    11/14/24 12:17:50 PM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Imunon Inc.

    SC 13G - Imunon, Inc. (0000749647) (Subject)

    8/5/24 11:53:32 AM ET
    $IMNN
    Biotechnology: Pharmaceutical Preparations
    Health Care